x

Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
April 27, 2018 Understanding Cancer Progression and Metastasis “Cancer progression” is the process by which this disease goes from bad to worse. Molecularly, the course of cancer progression is set by accumulation of mutations in genes, resulting in activation and inactivation of oncogenes and suppressor genes. At the cellular and tissue level, advanced cancers evade the immune system, stimulate the development of a ... LEARN MORE
April 5, 2018 The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often used to reduce system ... LEARN MORE
March 1, 2018 Using T Cells in Immuno-Oncology Immuno-oncology drug development challenges researchers to model the interaction between novel immunotherapy agents, ... LEARN MORE
January 5, 2018 2018 Technology Advances – Applying Next Generation Sequencing to Single Cell Analysis It is an axiom in biology that expression of genotype determines phenotype. This means, for the large part, that the ... LEARN MORE
October 12, 2017 Organ-on-a-Chip: The Future of Improved Drug Discovery? I’m a firm believer in the use of animal models in medical research. This is so for many reasons. A chemist and mentor ... LEARN MORE
September 12, 2017 CD137: An Important Target in T Cell Co-Stimulation Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell ... LEARN MORE
August 10, 2017 Tumor Necrosis Factor Superfamily of Ligands and Receptors 101 Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated function of a multitude of both innate and adaptive immune cells. These proteins play a role in the entire life-cycle of immune cells - differentiation, activation, inhibition, and even death. This means that many of the family members are coming ... LEARN MORE
July 11, 2017 Oncolytic Viruses: From History to Where We Go Next One of the more innovative weapons in our anticancer armamentarium has to be oncolytic viruses. Their rationale as an ... LEARN MORE
May 23, 2017 When to Use Conventional Cell Line Derived Xenograft Models With the creation and increased use of “new” xenograft models (such as patient-derived xenografts, or PDX), we are ... LEARN MORE
May 5, 2017 Patient-Derived Xenograft Population Studies: A Better Preclinical Representation of the Clinical Drug Development Process The most nerve wracking part of drug discovery is anxiously waiting for the first-in-man data. Is it safe? Will the ... LEARN MORE